1. |
Khawaja M, Thakker J, Kherallah R, et al. Antacid therapy in coronary artery disease and heart failure: proton pump inhibitors vs. H2 receptor blockers. Cardiovasc Drugs Ther, 2022, (6): 1-9.
|
2. |
Khan S, Mohammad A, O'Rourke KP. An audit of the frequency of proton pump inhibitor (PPI) prescription in rheumatoid arthritis (RA) patients taking non-steroidal anti-inflammatory drugs (NSAIDs). Ir J Med Sci, 2014, 183(4): 685-686.
|
3. |
Rückert-Eheberg IM, Nolde M, Ahn N, et al. Who gets prescriptions for proton pump inhibitors and why? A drug-utilization study with claims data in Bavaria, Germany, 2010-2018. Eur J Clin Pharmacol, 2022, 78(4): 657-667.
|
4. |
Lespessailles E, Toumi H. Proton pump inhibitors and bone health: an update narrative review. Int J Mol Sci, 2022, 23(18): 10733.
|
5. |
Hoffmann F, Glaeske G, Schmiemann G. Increased prescribing of proton pump inhibitors in ambulatory care over the years 2005-2013. Z Gastroenterol, 2015, 53(2): 95-100.
|
6. |
Singh A, Kirby DF, Cresci GA. Response to comment on 'proton pump inhibitors. Risks and rewards and emerging consequences to the gut microbiome'. Nutr Clin Pract, 2019, 34(1): 173.
|
7. |
Poly TN, Islam MM, Yang HC, et al. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int, 2019, 30(1): 103-114.
|
8. |
Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA, 2006, 296(24): 2947-2953.
|
9. |
Freedberg DE, Haynes K, Denburg MR, et al. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. Osteoporos Int, 2015, 26(10): 2501-2507.
|
10. |
Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone, 2011, 48(4): 768-776.
|
11. |
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010, 25(9): 603-605.
|
12. |
Davies HT, Crombie IK, Tavakoli M. When can odds ratios mislead. BMJ, 1998, 316(7136): 989-991.
|
13. |
Wang YH, Wintzell V, Ludvigsson JF, et al. Association between proton pump inhibitor use and risk of fracture in children. JAMA Pediatr, 2020, 174(6): 543-551.
|
14. |
Fleishman N, Richardson T, Attard T. The clinical characteristics of fractures in pediatric patients exposed to proton pump inhibitors. J Pediatr Gastroenterol Nutr, 2020, 70(6): 815-819.
|
15. |
Wagner K, Wagner S, Susi A, et al. Prematurity does not increase early childhood fracture risk. J Pediatr, 2019, 207: 148-153.
|
16. |
Malchodi L, Wagner K, Susi A, et al. Early acid suppression therapy exposure and fracture in young children. Pediatrics, 2019, 144(1): e20182625.
|
17. |
Fleishman NR, Richardson T, Attard TM. A multicenter cohort analysis of fractures in histamine-2-receptor antagonist treated pediatric patients. Curr Med Res Opin, 2022, 38(4): 565-570.
|
18. |
Freedberg DE, Lamousé-Smith ES, Lightdale JR, et al. Use of acid suppression medication is associated with risk for C. difficile infection in infants and children:a population-based study. Clin Infect Dis, 2015, 61(6): 912-917.
|
19. |
O'Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med, 2005, 118(7): 778-781.
|
20. |
Colin-Jones DG. The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther, 1995, 9(Suppl 1): 9-14.
|
21. |
Schuler A. Risks versus benefits of long-term proton pump inhibitor therapy in the elderly. Geriatr Nurs, 2007, 28(4): 225-229.
|
22. |
Takasugi S, Shioyama M, Kitade M, et al. Effects of proton pump inhibitor administration and intake of a combination of yogurt and galactooligosaccharides on bone and mineral metabolism in rats. Nutrients, 2016, 8(10): 653.
|
23. |
Yang YX. Proton pump inhibitor therapy and osteoporosis. Curr Drug Saf, 2008, 3(3): 204-209.
|
24. |
Maléth J, Hegyi P. Long-term proton pump inhibitor therapy and osteoporosis. Is there a real danger? Orv Hetil, 2013, 154(26): 1005-1009.
|
25. |
He T, Jin X, Koh YS, et al. The association of homocysteine, folate, vitamin B12, and vitamin B6 with fracture incidence in older adults: a systematic review and meta-analysis. Ann Transl Med, 2021, 9(14): 1143.
|
26. |
Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology, 2017, 152(4): 706-715.
|
27. |
Rosanoff A, Dai Q, Shapses SA. Essential nutrient interactions: does low or suboptimal magnesium status interact with vitamin D and/or calcium status. Adv Nutr, 2016, 7(1): 25-43.
|
28. |
Vinke P, Wesselink E, van Orten-Luiten W, et al. The use of proton pump inhibitors may increase symptoms of muscle function loss in patients with chronic illnesses. Int J Mol Sci, 2020, 21(1): 323.
|
29. |
Cea Soriano L, Ruigómez A, Johansson S, et al. Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting. Pharmacotherapy, 2014, 34(6): 570-581.
|
30. |
范修德, 尹盼盼, 王小云, 等. H2受体拮抗剂对髋部骨折风险影响的Meta分析. 中国循证医学杂志, 2016, 16(12): 1401-1407.
|